Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer

Peter Q. Huang, Brant C. Boren, Sayee G. Hegde, Hui Liu, Aditya K. Unni, Sunny Abraham, Chad D. Hopkins, Sunil Paliwal, Ahmed A. Samatar, Jiali Li, Kevin D. Bunker

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

Wee1 inhibition has received great attention in the past decade as a promising therapy for cancer treatment. Therefore, a potent and selective Wee1 inhibitor is highly desirable. Our efforts to make safer and more efficacious Wee1 inhibitors led to the discovery of compound 16, a highly selective Wee1 inhibitor with balanced potency, ADME, and pharmacokinetic properties. The chiral ethyl moiety of compound 16 provided an unexpected improvement of Wee1 potency. Compound 16, known as ZN-c3, showed excellent in vivo efficacy and is currently being evaluated in phase 2 clinical trials.

Original languageEnglish
Pages (from-to)13004-13024
Number of pages21
JournalJournal of Medicinal Chemistry
Volume64
Issue number17
DOIs
StatePublished - 9 Sep 2021

Fingerprint

Dive into the research topics of 'Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer'. Together they form a unique fingerprint.

Cite this